Daniel Halperin, MD
Medical Oncology · Houston, TXNPI 1801024161
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $85,361 of the $116,083 with a category attached, or 73.5%. It is spread thinly across 17 manufacturers, the largest accounting for just 18.4%. 2025 is the largest year on record at $30,112, 2.2 times the $13,898 reported in 2019.
Across 99 payments — averaging $1172.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$21K
- Advanced Accelerator Applications$14K
- Tersera Therapeutics LLC$13K
- Amryt Pharma Holdings Ltd$13K
- Ipsen Biopharmaceuticals, Inc$11K
- Boehringer Ingelheim$11K
- plus $33K from 11 others
Across 98 payments — averaging $9813.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Brahms GmbH$349K
- E.r. Squibb & Sons, L.L.C.$348K
- Novartis$220K
- Incyte Corporation$29K
- Tersera Therapeutics LLC$13K
- Novartis Pharma AG$2K
- plus $611 from 1 others
What the payments were for
- Consulting fees$85,36174%
- Speaking & faculty fees$21,18018%
- Travel & lodging$4,9764%
- Food & beverage$3,2403%
- Education$1,3261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 22 | $21,380 |
| Advanced Accelerator Applications | 5 | $13,818 |
| Tersera Therapeutics LLC | 9 | $13,144 |
| Amryt Pharma Holdings Ltd | 6 | $13,000 |
| Ipsen Biopharmaceuticals, Inc | 13 | $11,270 |
| Boehringer Ingelheim | 17 | $10,769 |
| Lexicon Pharmaceuticals, Inc. | 7 | $8,038 |
| AbbVie | 4 | $5,955 |
| Lantheus Medical Imaging, Inc. | 2 | $5,670 |
| Ipsen Bioscience Inc. | 1 | $5,220 |
| Novartis | 3 | $3,876 |
| Progenics Pharmaceuticals, Inc. | 3 | $2,575 |
| Curium US LLC | 3 | $1,100 |
| Seagen Inc. | 1 | $76 |
| Bristol Myers Squibb | 1 | $75 |
| Genentech, Inc. | 1 | $73 |
| Abbott | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,083 in reported general payments places this provider in the 85th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.